Zymeworks Acquires Theravance Biopharma for $929 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 40 minutes ago
0mins
Source: Newsfilter
- Acquisition Overview: Zymeworks is acquiring Theravance Biopharma for $17 per share, totaling approximately $929 million, with the transaction expected to close in the second half of 2026, significantly enhancing Zymeworks' product portfolio and revenue sources.
- Cash Flow Expectations: The acquisition of YUPELRI® is projected to generate around $60 million in annual cash flow for Zymeworks, alongside existing cash flows from Ziihera®, supporting ongoing investments in R&D and shareholder returns.
- Innovative Financing Structure: The acquisition is primarily financed through a $350 million non-recourse note, minimizing Zymeworks' capital risk while preserving financial flexibility, with an expected reduction of approximately 50% in net investment.
- Strategic Development Direction: Zymeworks plans to optimize its R&D and commercialization strategies by integrating Theravance Biopharma's assets, further driving long-term shareholder value creation, particularly in response to the growing market demand for COPD treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZYME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZYME
Wall Street analysts forecast ZYME stock price to rise
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.770
Low
30.00
Averages
35.55
High
42.00
Current: 23.770
Low
30.00
Averages
35.55
High
42.00
About ZYME
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zymeworks Acquires Theravance Biopharma for $929M
- Acquisition Overview: Zymeworks announced its acquisition of Theravance Biopharma in an all-cash deal valued at approximately $929 million, paying $17 per share, aimed at expanding its commercial portfolio with the COPD treatment YUPELRI.
- Financial Impact Analysis: YUPELRI currently generates about $60 million in annual cash flow, and the acquisition includes additional royalty interests, milestone payments, and approximately $2.5 billion in Irish tax attributes, which are expected to significantly enhance Zymeworks' financial position.
- Financing Structure: The deal will be financed primarily through a $350 million non-recourse note from OMERS Life Sciences, Theravance's expected $360 million net cash balance at closing, and $219 million of Zymeworks' cash, showcasing a diverse financing strategy.
- Approval and Expectations: The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026; however, TBPH stock dropped 3% in pre-market trading on Monday, indicating some market skepticism despite the deal's long-term strategic significance.
See More
Zymeworks Acquires Theravance Biopharma for $929 Million
- Acquisition Overview: Zymeworks is acquiring Theravance Biopharma for $17 per share, totaling approximately $929 million, with the transaction expected to close in the second half of 2026, significantly enhancing Zymeworks' product portfolio and revenue sources.
- Cash Flow Expectations: The acquisition of YUPELRI® is projected to generate around $60 million in annual cash flow for Zymeworks, alongside existing cash flows from Ziihera®, supporting ongoing investments in R&D and shareholder returns.
- Innovative Financing Structure: The acquisition is primarily financed through a $350 million non-recourse note, minimizing Zymeworks' capital risk while preserving financial flexibility, with an expected reduction of approximately 50% in net investment.
- Strategic Development Direction: Zymeworks plans to optimize its R&D and commercialization strategies by integrating Theravance Biopharma's assets, further driving long-term shareholder value creation, particularly in response to the growing market demand for COPD treatments.
See More
Gandeeva and Zymeworks Partner to Enhance Antibody Drug Discovery
- Partnership Background: Vancouver-based Gandeeva Therapeutics has partnered with Zymeworks to utilize cryo-electron microscopy (cryo-EM) for generating high-resolution structural data of antibody-antigen interfaces, thereby enhancing antibody drug discovery and development.
- Technical Breakthrough: Gandeeva scientists successfully determined the structure of a small and flexible antigen (<20 kDa) bound to a Fab fragment of an antibody developed by Zymeworks, visualizing the nine amino acids forming the antibody-binding epitope at a resolution of 2.6 Å, significantly improving the understanding of complex biological targets.
- Business Impact: Zymeworks' Chief Scientific Officer, Paul Moore, stated that knowledge of precise interactions at these challenging targets is crucial for selecting antibody leads and provides essential insights for optimizing biologics, potentially accelerating their drug development processes.
- Strategic Significance: Gandeeva's founder, Sriram Subramaniam, emphasized that obtaining near-atomic resolution cryo-EM structures is a game-changer, particularly in the context of accelerating AI-driven antibody design, as it offers rapid feedback for testing and validating antibodies, thereby enhancing overall R&D efficiency.
See More
ZW191 Shows Significant Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer Patients
- Clinical Data Highlights: ZW191 demonstrated a confirmed objective response rate (cORR) of 78.6% in platinum-resistant ovarian cancer patients, particularly excelling in FRα-positive individuals, indicating its potential to transform treatment paradigms for difficult-to-treat cancers.
- Survival Data: The median progression-free survival across all dose levels was reported at 7.6 months, suggesting a positive impact on extending patient survival, which further underscores the necessity for its clinical development.
- Tolerability Analysis: While 98% of patients experienced treatment-emergent adverse events (TEAEs), most were manageable, with 55% reporting grade 3 or higher events, indicating that ZW191's safety profile aligns with its promising clinical application.
- Dose Optimization Study Completion: The dose optimization phase of ZW191 has completed patient recruitment, with future development expected to inform dose selection between 6.4 mg/kg and 9.6 mg/kg, signaling a broad potential for clinical application.
See More
Zymeworks to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Zymeworks will participate in one-on-one meetings and a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 20, aiming to enhance investor interest in its multifunctional biotherapeutics pipeline.
- Innovation Summit Participation: The management will engage in a fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, further showcasing its innovative capabilities and market potential in cancer treatment.
- Global Healthcare Conference: Zymeworks is set to attend the 2026 Jefferies Global Healthcare Conference on June 3 in New York, conducting one-on-one meetings and a fireside chat to attract more investor attention to its drug development progress.
- Strategic Partnerships and Product Development: Zymeworks is advancing its HER2-targeted bispecific antibody Ziihera through strategic collaborations with BeOne Medicines and Jazz Pharmaceuticals, demonstrating its strong competitive position in the biopharmaceutical sector.
See More
Zymeworks' ZW191 Shows Promising Efficacy in Phase 1 Trials
- Clinical Trial Results: Zymeworks presented Phase 1 data for ZW191 at the AACR Annual Meeting, achieving a confirmed objective response rate of 56% in platinum-resistant ovarian cancer patients, with 68% showing tumor regression and 94% disease control, indicating its potential in treating recurrent cancers.
- Targeting Specific Cancers: ZW191 is designed to target folate receptor alpha in ovarian and endometrial cancers, delivering a drug payload directly to tumor cells, addressing the urgent need for effective treatments in patients lacking options after standard therapies.
- Safety Profile: ZW191 demonstrated good tolerability at doses up to 11.2 mg/kg, with 55% of patients experiencing grade 3 or higher treatment-emergent adverse events, primarily neutropenia, anemia, and thrombocytopenia, while grade 4 events were rare, indicating a manageable safety profile.
- Next Steps in Research: The study's Part 2a has completed enrollment across North America, Europe, and Asia-Pacific, with results expected to guide the recommended dose for further registration studies, and ZW191's unique design positions it as a potential best-in-class therapy for gynecological cancers.
See More
Zymeworks Acquires Theravance Biopharma for $929M
- Acquisition Overview: Zymeworks announced its acquisition of Theravance Biopharma in an all-cash deal valued at approximately $929 million, paying $17 per share, aimed at expanding its commercial portfolio with the COPD treatment YUPELRI.
- Financial Impact Analysis: YUPELRI currently generates about $60 million in annual cash flow, and the acquisition includes additional royalty interests, milestone payments, and approximately $2.5 billion in Irish tax attributes, which are expected to significantly enhance Zymeworks' financial position.
- Financing Structure: The deal will be financed primarily through a $350 million non-recourse note from OMERS Life Sciences, Theravance's expected $360 million net cash balance at closing, and $219 million of Zymeworks' cash, showcasing a diverse financing strategy.
- Approval and Expectations: The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026; however, TBPH stock dropped 3% in pre-market trading on Monday, indicating some market skepticism despite the deal's long-term strategic significance.
See More
Zymeworks Acquires Theravance Biopharma for $929 Million
- Acquisition Overview: Zymeworks is acquiring Theravance Biopharma for $17 per share, totaling approximately $929 million, with the transaction expected to close in the second half of 2026, significantly enhancing Zymeworks' product portfolio and revenue sources.
- Cash Flow Expectations: The acquisition of YUPELRI® is projected to generate around $60 million in annual cash flow for Zymeworks, alongside existing cash flows from Ziihera®, supporting ongoing investments in R&D and shareholder returns.
- Innovative Financing Structure: The acquisition is primarily financed through a $350 million non-recourse note, minimizing Zymeworks' capital risk while preserving financial flexibility, with an expected reduction of approximately 50% in net investment.
- Strategic Development Direction: Zymeworks plans to optimize its R&D and commercialization strategies by integrating Theravance Biopharma's assets, further driving long-term shareholder value creation, particularly in response to the growing market demand for COPD treatments.
See More
Gandeeva and Zymeworks Partner to Enhance Antibody Drug Discovery
- Partnership Background: Vancouver-based Gandeeva Therapeutics has partnered with Zymeworks to utilize cryo-electron microscopy (cryo-EM) for generating high-resolution structural data of antibody-antigen interfaces, thereby enhancing antibody drug discovery and development.
- Technical Breakthrough: Gandeeva scientists successfully determined the structure of a small and flexible antigen (<20 kDa) bound to a Fab fragment of an antibody developed by Zymeworks, visualizing the nine amino acids forming the antibody-binding epitope at a resolution of 2.6 Å, significantly improving the understanding of complex biological targets.
- Business Impact: Zymeworks' Chief Scientific Officer, Paul Moore, stated that knowledge of precise interactions at these challenging targets is crucial for selecting antibody leads and provides essential insights for optimizing biologics, potentially accelerating their drug development processes.
- Strategic Significance: Gandeeva's founder, Sriram Subramaniam, emphasized that obtaining near-atomic resolution cryo-EM structures is a game-changer, particularly in the context of accelerating AI-driven antibody design, as it offers rapid feedback for testing and validating antibodies, thereby enhancing overall R&D efficiency.
See More
ZW191 Shows Significant Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer Patients
- Clinical Data Highlights: ZW191 demonstrated a confirmed objective response rate (cORR) of 78.6% in platinum-resistant ovarian cancer patients, particularly excelling in FRα-positive individuals, indicating its potential to transform treatment paradigms for difficult-to-treat cancers.
- Survival Data: The median progression-free survival across all dose levels was reported at 7.6 months, suggesting a positive impact on extending patient survival, which further underscores the necessity for its clinical development.
- Tolerability Analysis: While 98% of patients experienced treatment-emergent adverse events (TEAEs), most were manageable, with 55% reporting grade 3 or higher events, indicating that ZW191's safety profile aligns with its promising clinical application.
- Dose Optimization Study Completion: The dose optimization phase of ZW191 has completed patient recruitment, with future development expected to inform dose selection between 6.4 mg/kg and 9.6 mg/kg, signaling a broad potential for clinical application.
See More
Zymeworks to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Zymeworks will participate in one-on-one meetings and a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 20, aiming to enhance investor interest in its multifunctional biotherapeutics pipeline.
- Innovation Summit Participation: The management will engage in a fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, further showcasing its innovative capabilities and market potential in cancer treatment.
- Global Healthcare Conference: Zymeworks is set to attend the 2026 Jefferies Global Healthcare Conference on June 3 in New York, conducting one-on-one meetings and a fireside chat to attract more investor attention to its drug development progress.
- Strategic Partnerships and Product Development: Zymeworks is advancing its HER2-targeted bispecific antibody Ziihera through strategic collaborations with BeOne Medicines and Jazz Pharmaceuticals, demonstrating its strong competitive position in the biopharmaceutical sector.
See More
Zymeworks' ZW191 Shows Promising Efficacy in Phase 1 Trials
- Clinical Trial Results: Zymeworks presented Phase 1 data for ZW191 at the AACR Annual Meeting, achieving a confirmed objective response rate of 56% in platinum-resistant ovarian cancer patients, with 68% showing tumor regression and 94% disease control, indicating its potential in treating recurrent cancers.
- Targeting Specific Cancers: ZW191 is designed to target folate receptor alpha in ovarian and endometrial cancers, delivering a drug payload directly to tumor cells, addressing the urgent need for effective treatments in patients lacking options after standard therapies.
- Safety Profile: ZW191 demonstrated good tolerability at doses up to 11.2 mg/kg, with 55% of patients experiencing grade 3 or higher treatment-emergent adverse events, primarily neutropenia, anemia, and thrombocytopenia, while grade 4 events were rare, indicating a manageable safety profile.
- Next Steps in Research: The study's Part 2a has completed enrollment across North America, Europe, and Asia-Pacific, with results expected to guide the recommended dose for further registration studies, and ZW191's unique design positions it as a potential best-in-class therapy for gynecological cancers.
See More
